Drug-induced Thrombotic Microangiopathy Caused by Gemcitabine

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2018 Oct 17

PMID 30324044

Citations 3

Authors

Askari Hasan

Akriti G Jain

Huda Naim

Alvina Munaf

George Everett

Affiliations

Soon will be listed here.

Abstract

Hemolytic uremic syndrome (HUS) is the triad of nonimmune (Coombs negative) hemolytic anemia, low platelet count, and renal impairment. HUS has been associated with a variety of gastrointestinal malignancies and chemotherapeutic agents. We present a patient with pancreatic cancer treated with gemcitabine for palliation who developed gemcitabine-induced HUS (GiHUS) which responded to some extent to blood and platelet transfusions. With the increase in the use of gemcitabine therapy for pancreatic and other malignancies, it is essential to accurately and timely diagnose GiHUS to avoid the life-threatening complications.

Citing Articles

Gemcitabine-Induced Thrombotic Microangiopathy in a Patient With Cholangiocarcinoma: An Atypical Case.

Anil V, Alhujaily E, Grover D, Santos J, Kanugula A, Suleiman M Cureus. 2024; 16(6):e63385.

PMID: 39070506 PMC: 11283843. DOI: 10.7759/cureus.63385.

Atypical Hemolytic Uremic Syndrome: Cancer-Induced or Chemotherapy-Induced?.

Sethi A, Moses R Cureus. 2021; 13(2):e13260.

PMID: 33717763 PMC: 7954088. DOI: 10.7759/cureus.13260.

An Update in Drug-Induced Thrombotic Microangiopathy.

Chatzikonstantinou T, Gavriilaki M, Anagnostopoulos A, Gavriilaki E Front Med (Lausanne). 2020; 7:212.

PMID: 32528969 PMC: 7256484. DOI: 10.3389/fmed.2020.00212.

References

Brodowicz T, Breiteneder S, Wiltschke C, Zielinski C . Gemcitabine-induced hemolytic uremic syndrome: a case report. J Natl Cancer Inst. 1997; 89(24):1895-6. DOI: 10.1093/jnci/89.24.1895. View

Ruggenenti P, Noris M, Remuzzi G . Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001; 60(3):831-46. DOI: 10.1046/j.1523-1755.2001.060003831.x. View

Hillyer C, Duncan A, Ledford M, Barrett T, Klumpp S, Anderson D . Chemotherapy-induced hemolytic uremic syndrome: description of a potential animal model. J Med Primatol. 1995; 24(2):68-73. DOI: 10.1111/j.1600-0684.1995.tb00148.x. View

Schieppati A, Ruggenenti P, Cornejo R, Ferrario F, Gregorini G, Zucchelli P . Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. The Italian Registry of Haemolytic Uremic Syndrome. J Am Soc Nephrol. 1992; 2(11):1640-4. DOI: 10.1681/ASN.V2111640. View

Monteagudo J, Pereira A, Roig S, Reverter J, Ordinas A, Castillo R . Investigation of plasma von Willebrand factor and circulating platelet aggregating activity in mitomycin C-related hemolytic-uremic syndrome. Am J Hematol. 1990; 33(1):46-9. DOI: 10.1002/ajh.2830330109. View

Walter R, Joerger M, Pestalozzi B . Gemcitabine-associated hemolytic-uremic syndrome. Am J Kidney Dis. 2002; 40(4):E16. DOI: 10.1053/ajkd.2002.35758. View

Carreras L, Romero R, REQUESENS C, OLIVER A, Carrera M, Clavo M . Familial hypocomplementemic hemolytic uremic syndrome with HLA-A3,B7 haplotype. JAMA. 1981; 245(6):602-4. View

Cantrell Jr J, Phillips T, Schein P . Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol. 1985; 3(5):723-34. DOI: 10.1200/JCO.1985.3.5.723. View

Glezerman I, Kris M, Miller V, Seshan S, Flombaum C . Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. Clin Nephrol. 2009; 71(2):130-9. DOI: 10.5414/cnp71130. View

10.

Hui Y, Reitz J . Gemcitabine: a cytidine analogue active against solid tumors. Am J Health Syst Pharm. 1997; 54(2):162-70; quiz 197-8. DOI: 10.1093/ajhp/54.2.162. View

11.

Hammar S, BLOOMER H, McCloskey D . Adult hemolytic uremic syndrome with renal arteriolar deposition of IgM andC3. Am J Clin Pathol. 1978; 70(3):434-9. DOI: 10.1093/ajcp/70.3.434. View

12.

Saif M, McGee P . Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature. JOP. 2005; 6(4):369-74. View

13.

Taylor C, Chua C, Howie A, Risdon R . Clinico-pathological findings in diarrhoea-negative haemolytic uraemic syndrome. Pediatr Nephrol. 2004; 19(4):419-25. DOI: 10.1007/s00467-003-1385-9. View

14.

Gordon L, Kwaan H . Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol. 1997; 34(2):140-7. View

15.

Izzedine H, Isnard-Bagnis C, Launay-Vacher V, Mercadal L, Tostivint I, Rixe O . Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant. 2006; 21(11):3038-45. DOI: 10.1093/ndt/gfl507. View

16.

Gianviti A, Rosmini F, Caprioli A, Corona R, Matteucci M, Principato F . Haemolytic-uraemic syndrome in childhood: surveillance and case-control studies in Italy. Italian HUS Study Group. Pediatr Nephrol. 1994; 8(6):705-9. DOI: 10.1007/BF00869095. View

17.

Kwaan H, Soff G . Management of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol. 1997; 34(2):159-66. View

18.

Montes A, Powles T, OBrien M, Ashley S, Luckit J, Treleaven J . A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. Eur J Cancer. 1993; 29A(13):1854-7. DOI: 10.1016/0959-8049(93)90537-p. View

19.

Remuzzi G, Galbusera M, Salvadori M, Rizzoni G, Paris S, Ruggenenti P . Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma. Kidney Int. 1996; 49(1):282-6. DOI: 10.1038/ki.1996.40. View

20.

Rother R, Rollins S, Mojcik C, Brodsky R, Bell L . Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007; 25(11):1256-64. DOI: 10.1038/nbt1344. View